

Announcement No. 6/2012

To NASDAQ OMX Copenhagen A/S

Exiqon A/S
Skelstedet 16
2950 Vedbæk
DenmarkPhone: +45 4566 0888
Fax: +45 4566 1888
exiqon@exiqon.com
www.exiqon.com
CVR/Tax Id: 18 98 44 31

29 March 2012

Exiqon A/S - Report regarding the management's and closely related parties' transactions with securities in Exiqon A/S

Pursuant to section 28a of the Danish Securities Trading Act, Exiqon A/S (NASDAQ OMX Copenhagen: "EXQ") hereby announces the management's and their closely related parties' transactions with shares and related securities in Exiqon A/S:

Name:	Lars Kongsbak
Reason for reporting:	Chief Executive Officer
Issuer:	Exiqon A/S
Type of transaction:	Grant
Type of security:	Warrant
Date of trade:	29 March 2012
Place of transaction:	-
Security code (ISIN code):	-
Traded securities (No.):	1,512,566
Market value in DKK of traded securities:	19,512,101.40

Name:	Hans Henrik Chrois Christensen
Reason for reporting:	Chief Financial Officer
Issuer:	Exiqon A/S
Type of transaction:	Grant
Type of security:	Warrant
Date of trade:	29 March 2012
Place of transaction:	-
Security code (ISIN code):	-
Traded securities (No.):	756,283
Market value in DKK of traded securities:	9,756,050.70

Additional information

Lars Kongsbak, CEO, phone +45 4566 0888 (cell: +45 4090 2101)

Hans Henrik Chrois Christensen, CFO, phone +45 4566 0888 (cell: +45 4090 2131)

About Exiqon

Exiqon's products are based on the proprietary LNA™ technology. This technology offers unique advantages for detection of miRNA biomarkers for life science researchers, drug developers and cancer treating physicians working towards personalizing medicine. Exiqon operates in two business areas: Exiqon Life Sciences has established a position for itself as one of the market's leading providers of miRNA research products for miRNA analysis in cells. Our research products are used by academia, biotech and pharmaceutical companies around the world to make groundbreaking discoveries about the correlation between gene activity and the development of cancer and other diseases. Exiqon Life Sciences is also collaborating with pharmaceutical companies in their effort to develop new medicines based on miRNA as biological markers (Exiqon Pharma Services). Exiqon Diagnostics collaborates with pharmaceutical and diagnostic companies to develop novel molecular diagnostic tests for early detection of diseases which can help physicians make treatment decisions. Exiqon is listed on the NASDAQ OMX in Copenhagen. For more information about us, please visit www.exiqon.com.

